Skip to main content

Table 2 Analysis of T CD4 lymphocyte expression of CD4+CD3+ and CD4+CD25hi, and CD86 activation markers in APCs

From: New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro

Treatment

Percent of cell phenotypes

 

CD4+CD3+

CD4+CD25hi

CD11b+CD86+

Medium

24.5 ± 8.2

0.5 ± 0.2

31.8 ± 7.1

Insulin

34.4 ± 3.8

1.2 ± 0.6

44.8 ± 8.6

Insulin + DNAhsp65

49.2 ± 6.8a

6.7 ± 1.6b

77.6 ± 5.1b

Insulin + Hsp65

42.8 ± 4.5a

9.6 ± 3.7b

69.3 ± 6.0b

Insulin + Hsp70

43.1 ± 3.9a

7.7 ± 1.7b

65.0 ± 7.4b

  1. Data are reported as means ± SD for 3 separate experiments
  2. a P < 0.05 compared to insulin group (t-test)
  3. b P < 0.001